Core Viewpoint - The review of the long-acting follicle-stimulating hormone has been suspended due to reaching the review deadline, and the company is currently awaiting supplementary comments [1] Company Summary - 双鹭药业 (Shuanglu Pharmaceutical) has communicated with investors regarding the status of its long-acting follicle-stimulating hormone review process [1]

Group 1 - The core issue is the suspension of the review for the long-acting follicle-stimulating hormone by the company due to reaching the review deadline and currently awaiting supplementary comments [2]